drugset / Trial / NCT02183324
BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese patients with type 2 diabetes mellitus.
Timeline
- Start
- 2007-02
- Primary completion
- 2007-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Small molecule | 0.5 mg | Oral |
| Subject | Linagliptin | Small molecule | 2.5 mg | Oral |
| Subject | Linagliptin | Small molecule | 10 mg | Oral |